From: The clinical features of the overlap between COPD and asthma
 | COPD Only | COPD and Asthma | p-value |
---|---|---|---|
Total Subjects | 796 | 119 | -- |
Race: | Â | Â | Â |
Non-Hispanic white | 672 (84.4) | 79 (66.4) | < 0.0001 |
African American | 124 (15.6) | 40 (33.6) | Â |
Gender | Â | Â | Â |
Male | 423 (53.1) | 61 (51.3) | 0.77 |
Female | 373 (46.9) | 58 (48.7) | Â |
Age, years | 64.7 (8.2) | 61.3 (8.9) | 0.0001* |
Pack-years of smoking | 55.1 (27.3) | 43.7 (20.7) | < 0.0001* |
Current smoker | 270 (34.2) | 46 (38.7) | 0.35 |
BMI kg/m2 | 27.8 (6.0) | 28.1 (6.7) | 0.87* |
GOLD Stage | Â | Â | Â |
2 | 408 (51.3) | 61 (51.3) | 0.99** |
3 | 251 (31.5) | 38 (31.9) | Â |
4 | 137 (17.2) | 20 (16.8) | Â |
BODE Index | 3.0 (2.1) | 3.2 (1.9) | 0.28* |
SGRQ | 38.6(20.5) | 44.0 (21.9) | 0.0075* |
6MWT (ft) | 1140.2 (431.9) | 1158.8 (430.1) | 0.78* |
Severe exacerbations | 140 (17.6) | 39 (32.8) | 0.0003 |
Frequent exacerbations | 114 (18.0) | 41 (42.7) | < 0.0001 |
Hay fever | 204 (27.8) | 65 (57.0) | < 0.0001 |
Inhaled corticosteroid use | 387 (49.4) | 80 (69.0) | 0.25*** |
FEV1 % predicted | 49.4 (18.4) | 49.2 (17.5) | 0.85* |
FVC % predicted | 76.6 (17.9) | 78.3 (17.3) | 0.23* |
FEV1/FVC | 0.48 (0.13) | 0.48 (0.12) | 0.62* |
Presence of bronchodilator response, ATS definition | 270 (36.0) | 46 (41.1) | 0.30 |
Post bronchodilator % change in FEV1 | 8.7 (12.1) | 10.2 (12.5) | 0.33* |
Percent Emphysema, -950HU | 15.8 (13.5) | 13.7 (12.3) | 0.18* |
Percent gas-trapping, -856HU | 42.1 (20.3) | 43.1 (20.5) | 0.69* |
Airway wall thickness Pi10 | 3.78 (0.12) | 3.80 (0.14) | 0.34* |